Zimbabwe has rejected a substantial American healthcare agreement valued at $367m (£272m) spanning five years due to Washington's demand for sensitive data.
This rejection became public following a government memo dated December was disclosed, revealing that Head of State Emmerson Mnangagwa believed the deal was "unbalanced".
A government representative later stated that the United States was seeking genetic material for scientific study and profit but was not willing to guarantee the resulting advantages from future treatments.
"We are forced to start the challenging and unfortunate task of winding down our support in Zimbabwe," stated American envoy to Zimbabwe Pamela Tremont publicly.
The US Embassy noted the US had provided more than $1.9bn for health programmes to Zimbabwe during the past two decades.
A medical body in Zimbabwe has called for continued negotiations to reach a deal suitable to all parties so the nation's critical HIV treatment initiative can be sustained.
Broader Context
This rejection follows a comparable situation in Kenya, where a high court halted a related deal with the US after legal challenges were raised about the security of citizens' medical information.
Since returning to the presidency recently, US President Donald Trump has drastically cut overseas assistance and closed the key foreign aid agency.
USAID had managed assistance for the American government, but Trump argued its expenditure was "wasteful" and his government was pursuing direct bilateral deals to enhance transparency and accountability.
According to reports, Sixteen African countries have to date signed similar agreements, representing over $18.3bn in committed funds.
Specifics of the Rejected Deal
The funds for Zimbabwe would have funded "HIV/Aids treatment and prevention, TB, malaria, maternal and child health, and disease outbreak preparedness.
"We are confident this cooperation would have delivered immense benefits for Zimbabwean communities, especially the 1.2 million currently receiving HIV treatment via American-funded initiatives," Tremont added.
However, official spokesman Nick Mangwana argued the arrangement was "unequal".
"Our nation was requested to share its biological resources and data indefinitely, without any corresponding guarantee of access to any scientific breakthroughs – such as vaccines, diagnostics, or treatments – that could result from that shared data," he stated.
"Effectively, our nation would provide the basic resources for medical research with no assurance that the final treatments would be accessible to our people if a new disease outbreak arise."
National Interest and International Frameworks
Mangwana further pointed out that the American exit from the global health body and its push of bilateral deals were disrupting frameworks previously established through the international health agency.
Mangwana cited its Pandemic Benefit-Sharing system designed to deal with potential global health emergencies.
"This mechanism is intended to ensure that when a nation contributes its samples, the resulting advantages – including vaccines and treatments – are distributed fairly, not monopolised solely by those with the capability to create them."
The government's concerns over the US deal "should not be misconstrued as anti-American sentiment," he added.
"We are open to ongoing dialogue with our US partners on how future collaboration could be structured in a way that respects the independence and interests of each country."
Medical Community Reaction
Medical experts expressed it recognised the official position, but urged that talks need to persist considering much of the country's HIV programmes depended on international support.
"Where specific concerns arise, including those relating to data governance or implementation frameworks, these can often be resolved via detailed discussion and negotiated safeguards," the group said.
The situation highlights the continuing debate between accepting much-needed foreign assistance and protecting a country's data in an ever more interconnected world.